Olsson Hans, Halldin Christer, Farde Lars
Psychiatry Section, Department of Clinical Neuroscience, Karolinska Hospital, S-171 76 Stockholm, Sweden.
Neuroimage. 2004 Jun;22(2):794-803. doi: 10.1016/j.neuroimage.2004.02.002.
Dopaminergic neurotransmission in extrastriatal regions may play a crucial role in the pathophysiology and treatment of neuropsychiatric disorders. The high-affinity radioligands [(11)C]FLB 457, [(123)I]epidepride, and [(18)F]fallypride are now used in clinical studies to measure these low-density receptor populations in vivo. However, a single determination of the regional binding potential (BP) does not differentiate receptor density (B(max)) from the apparent affinity (K(D)). In this positron emission tomography (PET) study, we measured extrastriatal dopamine D2 receptor density (B(max)) and apparent affinity (K(D)) in 10 healthy subjects using an in vivo saturation approach. Each subject participated in two to three PET measurements with different specific radioactivity of [(11)C]FLB 457. The commonly used simplified reference tissue model (SRTM) was used in a comparison of BP values with the B(max) values obtained from the saturation analysis. The calculated regional receptor density values were of the same magnitude (0.33-1.68 nM) and showed the same rank order as reported from postmortem studies, that is, in descending order thalamus, lateral temporal cortex, anterior cinguli, and frontal cortex. The affinity ranged from 0.27 to 0.43 nM, that is, approximately 10-20 times the value found in vitro (20 pM). The area under the cerebellar time activity curve (TAC) was slightly lower (11 +/- 8%, mean +/- SD, P = 0.004, n = 10) after injection of low as compared with high specific radioactivity, indicating sensitivity to the minute density of dopamine D2 receptors in the this region. The results of the present study support that dopamine D2 receptor density and affinity can be differentiated in low-density regions using a saturation approach. There was a significant (P < 0.001) correlation between the binding potential calculated with SRTM and the receptor density (B(max)), which supports the use of BP in clinical studies where differentiation of B(max) and K(D) is not required. In such studies, the mass of FLB 457 has to be less than 0.5 microg injected to avoid a mass effect of the radioligand itself.
纹状体以外区域的多巴胺能神经传递可能在神经精神疾病的病理生理学和治疗中起关键作用。高亲和力放射性配体[(11)C]FLB 457、[(123)I]表哌立登和[(18)F]法利哌啶目前用于临床研究,以在体内测量这些低密度受体群体。然而,单次测定区域结合潜能(BP)并不能区分受体密度(Bmax)和表观亲和力(KD)。在这项正电子发射断层扫描(PET)研究中,我们使用体内饱和法测量了10名健康受试者纹状体以外区域的多巴胺D2受体密度(Bmax)和表观亲和力(KD)。每位受试者使用不同比放射性的[(11)C]FLB 457参与两到三次PET测量。在将BP值与从饱和分析获得的Bmax值进行比较时,使用了常用的简化参考组织模型(SRTM)。计算出的区域受体密度值大小相同(0.33 - 1.68 nM),并且显示出与死后研究报告相同的排序,即从高到低依次为丘脑、颞叶外侧皮质、前扣带回和额叶皮质。亲和力范围为0.27至0.43 nM,即约为体外发现值(20 pM)的10 - 20倍。与高比放射性注射后相比,低比放射性注射后小脑时间 - 活性曲线(TAC)下面积略低(11±8%,平均值±标准差,P = 0.004,n = 10),表明对该区域多巴胺D2受体的微小密度敏感。本研究结果支持使用饱和法在低密度区域区分多巴胺D2受体密度和亲和力。用SRTM计算的结合潜能与受体密度(Bmax)之间存在显著(P < 0.001)相关性,这支持在不需要区分Bmax和KD的临床研究中使用BP。在这类研究中,注射的FLB 457质量必须小于0.5微克,以避免放射性配体本身的质量效应。